Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression

Baohua Zhao1, Aihua Song, Rizwanul Haque

  • 1Department of Microbiology and Immunology and Pennsylvania State Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

Insights

Combining Bcl-x(L) and survivin enhances CD8(+) T cell expansion and survival, boosting anti-tumor activity. These findings suggest a novel strategy for augmenting cellular immunotherapy in cancer treatment.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Costimulation is crucial for T cell proliferation, expansion, and survival.
  • Bcl-x(L) and survivin are key anti-apoptotic molecules targeted by costimulatory signals in T cells.
  • The precise relationship and cooperative functions of Bcl-x(L) and survivin in primary T cells remain unclear.

Purpose of the Study:

  • To investigate the cooperative or overlapping functions of Bcl-x(L) and survivin in CD8(+) T cells.
  • To determine the impact of co-expressing Bcl-x(L) and survivin on T cell accumulation, persistence, and anti-tumor activity.

Main Methods:

  • Retrovirus-mediated transduction was used to introduce Bcl-x(L) and survivin into Ag-responding CD8(+) T cells.
  • Cells were engineered to express Bcl-x(L) and survivin separately or together.
  • In vivo studies involved adoptive T cell transfer into tumor-bearing models to assess anti-tumor efficacy.

Main Results:

  • Co-expression of Bcl-x(L) and survivin led to significantly enhanced early-stage expansion of CD8(+) effector T cells.
  • T cells expressing both molecules exhibited a prolonged survival advantage compared to those expressing either alone.
  • In vivo, CD8(+) T cells expressing both Bcl-x(L) and survivin demonstrated superior tumor protective activity.

Conclusions:

  • Bcl-x(L) and survivin cooperate in a nonredundant manner to enhance CD8(+) T cell accumulation and persistence post-antigen encounter.
  • Sustained costimulatory signals may be necessary to maintain the synergistic effects of Bcl-x(L) and survivin.
  • This study proposes a novel approach to enhance cellular immunotherapy for cancer by augmenting T cell function.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...